Evidence-based online course aims to improve health literacy and raise awareness about adult immunisation in India
Biocon Foundation, in association with IISc and TANUH, convened national experts at the 7th Oral Cancer Task Force Annual Conference to advance India’s oral cancer elimination roadmap
US-based Mylan Inc. divests entire holding of 9.19 million shares in Biocon
The launch comes as AI models rapidly expand the ability to generate hundreds or thousands of antibody candidates in a single design cycle
CDSCO approval authorises the sale and distribution of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab, for adult and paediatric patients aged 12 years and above with unresectable or metastatic melanoma
The FDA’s Fast Track designation highlights the potential of Lu AH69593 to address a significant unmet need in narcolepsy treatment
At the second edition of Indian Pharma Post E-Conference, India’s brightest scientific minds outline the innovation, manufacturing and policy priorities needed for India to emerge as a global biologics powerhouse
The Indian approval is supported by Takeda's global clinical development program comprising 19 Phase I, II and III clinical trials involving more than 28,000 participants
Innovator semaglutide becomes India's first and only GLP-1 receptor agonist approved for adults with non-cirrhotic MASH and moderate-to-advanced liver fibrosis
Proposed acquisition strengthens Samsung Biologics' presence in peptide therapeutics, including GLP-1s, and expands its footprint across the US, Europe and India
The global biopharma company said the CALM-1 study achieved its primary endpoint
Shilpa will develop and exclusively manufacture the cancer immunotherapy biosimilar, while Orion secures exclusive commercial rights across Europe.
The partnership aims to generate critical clinical evidence, strengthen domestic capabilities in advanced therapeutics and make cutting-edge cancer treatments more accessible and affordable for Indian patients
India conducts only about 4% of global clinical trials, while annual pharmaceutical R&D spending remains at $2–3 billion, compared with $70–75 billion in the US
Collaboration combines Formycon’s biosimilar development expertise with OneSource’s integrated biologics manufacturing platform for global markets
Recognition highlights company's people-first culture and contribution to healthcare access, community development and nation-building
The product will be offered as a pre-filled, multi-dose injectable pen in two strengths—2 mg/1.5 mL and 4 mg/3 mL—enabling flexible once-weekly dosing
Both the companies are evaluating pharmaceutical-grade ingredients with established safety profiles as potential excipients for biologic formulations
Under the licensing agreement, AstraZeneca will pay $600 million upfront, with up to $900 million in additional payments tied to development, regulatory and commercial milestones
A key highlight will be the latest findings from the global Phase-3 Masupirdine study, including demographic and clinical characteristics of enrolled patients
Subscribe To Our Newsletter & Stay Updated
